Variation Timelines and Grace Periods under EDREX GL.CAMD.003

1. Key takeaways

The Egyptian variation process runs on five clocks. Acceptance: feedback of acceptance, rejection or suspension for completion within 8 working days of submission (5 working days on the fast track). Suspension: where documents are not completed according to the checklist, a maximum of 90 working days, after which the application is cancelled. Evaluation: completion requirements issued on the platform within 25 working days of receiving the dossier (10 working days on the fast track). Completion: if the applicant does not follow up for 60 working days, the dossier is archived, the application is cancelled and the marketing grace period is suspended. Grace period: one year from acceptance of the variation request.

None of these clocks matches the registration timelines, and the suspension limit is expressed in working days rather than calendar days. Companies running parallel registration and variation projects must therefore maintain separate schedules, and the 60-working-day follow-up rule deserves its own alert because its consequences extend beyond cancellation to the legality of ongoing sales.

2. Legal basis

3. Expert insights

Insight 1: variation clocks (8 / 5 acceptance and 25 / 10 evaluation) are longer than registration clocks (5 / 3 and 20 / 7).

The two procedures are not aligned. Companies managing parallel project lines cannot transfer the registration timelines of 5 and 20 working days onto variations — variations run on 8 / 5 working day acceptance and 25 / 10 working day evaluation.

Insight 2: the suspension cap in variations is 90 working days, not the 90 days of the import approval.

Section 5.1 speaks of a maximum period of 90 working days, whereas Section 4.1.1 of GL.CAMD.007 uses a period of 90 days. The units differ: the variation suspension is counted in working days, making its real calendar length longer. Scheduling tools must distinguish the two.

Insight 3: after completing the documents there is still a hard-copy dossier step.

Section 5.3: once all variation documents are complete on the platform, an appointment must be arranged for the applicant’s registration representative to submit the hard-copy dossier (where required). Egyptian variations therefore run on a dual electronic plus paper track — completion on the platform is not the end of the procedure.

Insight 4: the evaluating body switches with the type of change, which explains why 25 working days only covers issuing completion requirements.

Section 5.2: devices may require a scientific opinion from the Central Administration for Pharmacovigilance, the specialised scientific committee or the device stability and biocompatibility committee for certain changes (applying to the situations listed in the general requirements). Section 5.3 then provides that once complete, evaluation is carried out by the specialised device registration committee or the Central Administration, and upon approval an updated registration licence stating the approved variations is issued.

Insight 5: the consequences of 60 working days without follow-up are threefold.

The note to Section 5.3: if the applicant does not follow up on the dossier for 60 working days, the dossier is archived, the application is cancelled, and the grace period for marketing the device in Egypt is suspended; an applicant wishing to resubmit must follow the same steps as before. The third consequence is the most easily overlooked — the grace period is what allows Tell and Do variations to keep selling while pending, so its suspension immediately affects the legality of sales.

Insight 6: the one-year grace period is the core buffer of the variation system and recurs across provisions.

Section 5.1 grants a one-year grace period to market in Egypt from the acceptance date of the variation request; Section 6.1 grants a one-year grace period for Tell and Do variations from acceptance of the documents; and Section 10 reconfirms one year from the initial acceptance of the variation request. All three provisions agree on the acceptance date as the starting point.

Insight 7: even a failed licence transfer ends with a one-year grace period safety net.

At the end of item A of Section 8: where any document required for the transfer cannot be submitted, the new applicant must submit a new registration application, but a one-year grace period to import the device is granted from the acceptance of the documents by the device evaluation administration; the stated reason is that the device is already circulating in the Egyptian market and difficulties of use should be avoided. It is a transitional arrangement designed to prevent supply interruption for devices already in circulation.

4. Practical recommendations

1. Schedule on 8 / 5 and 25 / 10 separately: do not recycle the registration timelines of 5 and 20.
2. Manage the suspension against 90 working days: distinguish it from the 90 days of the import approval.
3. Book the hard-copy dossier submission proactively after completion: platform completion is not the end.
4. Set a hard 60-working-day reminder: beyond it the dossier is archived, the application cancelled and the grace period suspended.
5. Record the grace period start date uniformly as the acceptance date and plan backwards over one year.
6. Anticipate the evaluating body: pharmacovigilance, the scientific committee and the stability committee may all be involved.
7. Activate the one-year grace period safety net when transfer documents are incomplete: start the new registration application in parallel.

5. Verification checklist

• □ Acceptance has been planned against the 8 / 5 working day clocks
• □ Evaluation has been planned against the 25 / 10 working day clocks
• □ Reminders are set for the 90 working day suspension cap
• □ The appointment for hard-copy dossier submission after completion has been arranged
• □ The 60 working day no-follow-up risk is on the dashboard
• □ The grace period start date (acceptance date) is recorded and planned backwards over one year
• □ The possible evaluating bodies (pharmacovigilance / scientific committee / stability committee) have been anticipated
• □ The fallback of a new registration plus one-year grace period for a failed transfer is prepared

Regulatory information verified as of 29 October 2026. The variation timelines and grace periods described here follow the current text of Sections 5.1–5.3 and Section 10 of EDREX: GL.CAMD.003 Version 3.

• Local resource in Egypt: GRZAN assists manufacturers from the Chinese mainland and other overseas markets in engaging the Egyptian Drug Authority (EDA) for medical device registration, import approvals and variation applications, including design of the registration applicant scheme (importing company, local factory or scientific office), preparation for scientific committee evaluation, analysis of pathways for obtaining free sale certificates from reference countries, Arabic localisation of labels and instructions for use, and setup of vigilance systems and periodic reporting.
• Service capabilities: product attribute determination and risk classification (devices Class I–III / IVD Class A–D), registration and re-registration, applicability assessment of system registration and bundled registration, three-category variation determination, import approvals and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; info@grzanglobal.com; website www.grzan.cn.